ThermoGenesis Holdings, Inc. · OTC:THMO
ThermoGenesis — Cesca Therapeutics — Biotech Showcase 2018
21 slides from ThermoGenesis's conference presentation, Jan 16, 2018
Slide 1: Chris Xu, Ph.D. Chairman and CEO, Biotech Showcase
Exhibit 99.1 Chris Xu, Ph.D. Chairman and CEO Biotech Showcase January 9, 2018
Slide 2: Forward looking statement
Forward looking statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current views and assumpt
Slide 3: Quick financial snapshot
Bae ee Ne 50 ie 38 oe oe oe oe eee ieee Quick financial snapshot Share Price* $3.21 52-Week Range $2.62 - $6.44 Shares Outstanding** 10.9M Market Capitalization $35.0M Revenue (TTM)*** $14M Cash*** $2.5M Largest Shareholder Boyalife Group (63%) Warrants Outstanding**** 4.1M * January 5, 2018 a 1 off
Slide 4: CAR-T is a major advancement in I/O cell therapy
Bae ee Ne 50 ie 38 oe oe oe oe eee ieee Car-Tis a major advancement in I/O cell therapy + 70+ U.S.-registered trials underway * 70-92% Complete Response rates for relapsed/refractory Acute Lymphoblastic Leukemia (ALL); impressive early clinical results in other hematologic cancers + Breakthrough the
Slide 5: First CAR-T therapy approved
irst CAR-T therapy approved ( /per patient) Science, 2006 October 6: 314(5796): 126-129. Emily's Story: A Young Girl Beats Cancer with Immunotherapy Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth S. H
Slide 6: Why is CAR-T so expensive? Manual manufacturing processes
hy is CAR-T so expensive? — the manual manufacturing processes Labor-intensive manual steps, highly variable, open systems, low yield, low efficiency > high cost The Short Version: Isolate (Collect) 6 | NASDAQ: KOOL
Slide 7: Why does CAR-T cell process efficiency matter?
Ee S95 50 N50 5 9 oe 8 os a a a hee ieee Why does CAR-T cell process efficiency matter? ~ 7 “Because refractory B cell malignancies can progress quickly, it is important to reduce the time between apheresis of patient PBMCs and Time to patient is a matter of administration of the engineered T cells.
Slide 8: Our product portfolio
Our product portfolio — In July, 2017, Cesca acquired SynGer' to develop automation for CAR-T therapies || BioBanking | Point-of-Care Cesca Product SynGen Product 1 On July 10, 2017, Cesca Therapeutics announced that its wholly-owned subsidiary, ThermoGenesis Corp., acquired the cell processing syst
Slide 9: Development of CAR-TXpress platform
Development of CAR-TXpress™ platform —— Automated system for large scale manufacturing of CAR-T cells with high efficiency :* joleBlood BMA. Leukapheresis Unit IL-2, CD3, Volumes May Exceed 5 L DNA Gene Insertion Additional IL-2 Infused Selection of CI Volume aa ea a [ Se Dama Redcoanest 4 10-14 day
Slide 10: Core technology — X-LAB for high efficiency cell isolation
Core technology — X-LAB™ for high efficiency cell isolation —WNon-ficoll based isolation of MNCs from various sources (blood, leukopheresis) Advantage: No ficoll use ASmLMedium] predepositedin T harvest chamber ‘axis ofrotation of awing bucket centrfugeis parllelto the floor 2000%9, 20 min 50x93 min
Slide 11: Core technology — buoyance activated cell sorting (BACS)
Core technology — buoyance activated cell sorting (BACS) What It Is: + BACS uses microscopic bubbles (each smaller than a single cell) as cell isolation reagents. * The microbubbles are ruggedized with lipid shells, to which antibodies are attached to bind them only to the target cell type in a mixt
Slide 12: Core technology — X-WASH for washing & reformulation
Core technology — X-WASH™ for washing & reformulation — High efficiency washing and re-formulation technology Cell suspension added to buffer in central chamber; buffer added to harvest chamber Car ige snapped on to Control Module, placed in centrifuge (3] Retrieve Washed Cells ‘Washed cells re-susp
Slide 13: Processing report for CGMP/CMC compliance
Processing report for CGMP/CMC compliance —— CAR-TXpress™ is designed to be in compliance with CMC manufacturing requirement SynGenx Processing Report Unie 1D: cm54 F-Reg (Ca a ie cma Time (Seconds) Depletion Valve Open Duration (sec): Harvest Valve open Duration (sec): Harvest Target Volume (mt): C
Slide 14: CAR-TXpress platform — a major leap in CMC manufacturing
Car-txpress platform — a major leap in CMC manufacturing —— Semi-automated system for large scale manufacturing of CAR-T cells with high efficiency X-LAB MNC Isolation | wo Ld “— [oF pees ABoyale Company Hours ° 2 3 4 14 | NASDAQ: KOOL
Slide 15: CAR-TXpress platform — a major leap in CMC manufacturing
Car-txpress platform — a major leap in CMC manufacturing —— Semi-automated system for large scale manufacturing of CAR-T cells with high efficiency oa 94.3 70 65.0 50 m= MNC Isolation MLMINC & CD3+ Selection % Recovery 30 20 10 o+ X-LAB &X-BACS* Ficoll & Magnetic Beads*# * Internal Data ** Red blood
Slide 16: Intellectual property — CAR-TXpress Platform
Intellectual property-— CAR-TXpress™ Platform I. Protects X-LAB, X-WASH, X-BACS “System for purifying certain cell populations by depleting others” Apparatus Claims Issued: USA, Australia, Canada, China, Japan, Malaysia, Mexico, Russia, Singapore (2012-2017) Pending: Europe, India, South Korea Metho
Slide 17: Growth strategy
Growth strategy Our goal is to become the leading provider of closed-system automation for cell-based therapeutics by capturing the rapidly growing immuno-oncology market. A Cc =) Stem Cell & CAR-T & Regenerative Medicine Immuno-Oncology Device Clinical CAR-TXpress™ “~~ Ss os BioBanking Point-of-Car
Slide 18: What we accomplished in 2017
BO 502050 5050 28 28 22 28 oe 2 oe oe ee ee ees What we accomplished in 2017 Implementation of new strategic vision and corporate goals Strengthened board of directors New executive team with proven track record: CEO & COO Closed strategic acquisition of SynGen Inc. Secured international distributio
Slide 19: Investment highlights
Bae ee Ne 50 ie 38 oe oe oe oe eee ieee Investment highlights > Well-positioned to be a leading player in automated CAR-T and CAR-NK cell CMC manufacturing > Able to leverage the strong growth of the immuno-oncology market > Strong IP position > CAR-TXpress™ to be a platform technology for diverse a
Slide 20: Experienced leadership team
Experienced leadership team OBc EDR 20 | NASDAQ: KOOL Chris Xu, PhD/MBA, Chairman, President and Chief Executive Officer Boyalife Group (founder), Pfizer, Founder Group Joined Cesca in March 2016 as Director, becoming CEO in Nov 2016 Vivian Liu, Chief Operating Officer and Director OxOnc Services Co
Slide 21: Investor Contact
Investor Contact: Paula Schwartz RX Communications pschwartz@rxir.com 917-322-2216 Thank You!